Veracyte (NASDAQ:VCYT) reported Q4 EPS of ($0.05), $0.11 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $80.3 million versus the consensus estimate of $74.94 million.
GUIDANCE:
Veracyte sees FY2023 revenue of $325-335 million, versus the consensus of $329.6 million.